A study revealed that Jun13296, a novel PLpro inhibitor, demonstrates potent antiviral and anti-inflammatory effects in vivo, offering hope for future COVID-19 therapies beyond Paxlovid.
Study: Design of quinoline SARS-CoV-2 papain-like protease inhibitors as oral antiviral drug candidates . Image Credit: Shutterstock AI Generator / Shutterstock.com
A study recently published in…
